Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

BACKGROUND: Patients with cancer who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with those without cancer. The impact of immune checkpoint inhibition (ICI) on the severity of COVID-19 illness is unknown. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogiers, Aljosja, Pires da Silva, Ines, Tentori, Chiara, Tondini, Carlo Alberto, Grimes, Joseph M, Trager, Megan H, Nahm, Sharon, Zubiri, Leyre, Manos, Michael, Bowling, Peter, Elkrief, Arielle, Papneja, Neha, Vitale, Maria Grazia, Rose, April A N, Borgers, Jessica S W, Roy, Severine, Mangana, Joanna, Pimentel Muniz, Thiago, Cooksley, Tim, Lupu, Jeremy, Vaisman, Alon, Saibil, Samuel D, Butler, Marcus O, Menzies, Alexander M, Carlino, Matteo S, Erdmann, Michael, Berking, Carola, Zimmer, Lisa, Schadendorf, Dirk, Pala, Laura, Queirolo, Paola, Posch, Christian, Hauschild, Axel, Dummer, Reinhard, Haanen, John, Blank, Christian U, Robert, Caroline, Sullivan, Ryan J, Ascierto, Paolo Antonio, Miller Jr, Wilson H, Stephen Hodi, F, Suijkerbuijk, Karijn P M, Reynolds, Kerry L, Rahma, Osama E, Lorigan, Paul C, Carvajal, Richard D, Lo, Serigne, Mandala, Mario, Long, Georgina V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817383/
https://www.ncbi.nlm.nih.gov/pubmed/33468556
http://dx.doi.org/10.1136/jitc-2020-001931

Ejemplares similares

Ejemplares similares